Carisma Therapeutics, Inc. (W2J.F)
| Previous close | 1.5190 |
| Open | 1.4700 |
| Bid | 1.4510 x N/A |
| Ask | 1.5190 x N/A |
| Day's range | 1.4690 - 1.4700 |
| 52-week range | 1.4690 - 8.6000 |
| Volume | |
| Avg. volume | 222 |
| Market cap | 61.026M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksCarisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organiz
- PR Newswire
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting taking place from May 31- June 4, 2024, in Chicago, IL.
